Home > Press > Metabolon closes on $5.3M in series C funding
![]() |
Abstract:
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that it has closed $5.3 million of an anticipated $11 million Series C funding round. This first portion closed on April 30, with the balance expected within the next 60 to 90 days.
"Our technology has been proven for biomarker discovery through hundreds of studies with many industry-leading partners. As a result, our service business has been very successful and continues to grow," said John Ryals, chief executive at Metabolon. "Our Series C funding will help to launch our diagnostics business with exciting products in prostate cancer and insulin resistance."
Metabolon offers global biochemical profiling (metabolomic) services to researchers working in drug safety and toxicology, bioprocess optimization, consumer products and other areas which benefit from insight into complex biochemical processes and how they change in response to experimental variables.
The company's technology has been used to identify biochemical biomarkers useful for the development of a wide range of diagnostics. These markers are being applied to the development of its own proprietary diagnostic tools for insulin resistance and prostate cancer*. Metabolon also offers research tools based on these biomarkers for investigators.
####
About Metabolon, Inc.
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization.
For more information, please click here
Contacts:
Metabolon, Inc.
800 Capitola Drive, Suite 1
Durham, NC 27713
Phone: 919.572.1711
Fax: 919.572.1721
Copyright © Metabolon, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Announcements
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |